{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:40:22Z","timestamp":1793173222269,"version":"4.5.0"},"reference-count":72,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,7,1]]},"abstract":"<jats:p>BACKGROUND. The prevalence of pervasive developmental disorders has increased in recent years. Links with the measles component of the measles-mumps-rubella vaccine and the cumulative exposure to thimerosal through other vaccines have been postulated.<\/jats:p>\n                  <jats:p>OBJECTIVES. The purpose of this work was to estimate the pervasive developmental disorder prevalence in Montreal, Canada, in cohorts born from 1987 to 1998 and evaluate the relationship of trends in pervasive developmental disorder rates with: (1) changes in cumulative exposure to ethylmercury (thimerosal) occurring through modifications in the immunization schedule of young children and (2) trends in measles-mumps-rubella vaccination use rates and the introduction of a 2\u2013measles-mumps-rubella dosing schedule during the study period.<\/jats:p>\n                  <jats:p>METHODS. We surveyed 27749 children born from 1987 to 1998 attending 55 schools from the largest Anglophone school board. Children with pervasive developmental disorders were identified by a special needs team. The cumulative exposure by age 2 years to thimerosal was calculated for 1987\u20131998 birth cohorts. Ethylmercury exposure ranged from medium (100\u2013125 \u03bcg) from 1987 to 1991 to high (200\u2013225 \u03bcg) from 1992 to 1995 to nil from 1996 onwards when thimerosal was entirely discontinued. Measles-mumps-rubella coverage for each birth cohort was estimated through surveys of vaccination rates. The immunization schedule included a measles-mumps-rubella single dose at 12 months of age up to 1995, and a second measles-mumps-rubella dose at 18 months of age was added on after 1996.<\/jats:p>\n                  <jats:p>RESULTS. We found 180 children (82.8% males) with a pervasive developmental disorder diagnosis who attended the surveyed schools, yielding a prevalence for pervasive developmental disorder of 64.9 per 10000. The prevalence for specific pervasive developmental disorder subtypes were, for autistic disorder: 21.6 of 10000; for pervasive developmental disorder not otherwise specified: 32.8 of 10000; and for Asperger syndrome: 10.1 of 10000. A statistically significant linear increase in pervasive developmental disorder prevalence was noted during the study period. The prevalence of pervasive developmental disorder in thimerosal-free birth cohorts was significantly higher than that in thimerosal-exposed cohorts (82.7 of 10000 vs 59.5 of 10000). Using logistic regression models of the prevalence data, we found no significant effect of thimerosal exposure used either as a continuous or a categorical variable. Thus, thimerosal exposure was unrelated to the increasing trend in pervasive developmental disorder prevalence. These results were robust when additional analyses were performed to address possible limitations because of the ecological nature of the data and to evaluate potential effects of misclassification on exposure or diagnosis. Measles-mumps-rubella vaccination coverage averaged 93% during the study interval with a statistically significant decreasing trend from 96.1% in the older birth cohorts (1988\u201389) to \u223c92.4% in younger birth cohorts (1996\u20131998). Thus, pervasive developmental disorder rates significantly increased when measles-mumps-rubella vaccination uptake rates significantly decreased. In addition, pervasive developmental disorder prevalence increased at the same rate before and after the introduction in 1996 of the second measles-mumps-rubella dose, suggesting no increased risk of pervasive developmental disorder associated with a 2\u2013measles-mumps-rubella dosing schedule before age 2 years. Results held true when additional analyses were performed to test for the potential effects of misclassification on exposure or diagnostic status. Thus, no relationship was found between pervasive developmental disorder rates and 1- or 2-dose measles-mumps-rubella immunization schedule.<\/jats:p>\n                  <jats:p>CONCLUSIONS. The prevalence of pervasive developmental disorder in Montreal was high, increasing in recent birth cohorts as found in most countries. Factors accounting for the increase include a broadening of diagnostic concepts and criteria, increased awareness and, therefore, better identification of children with pervasive developmental disorders in communities and epidemiologic surveys, and improved access to services. The findings ruled out an association between pervasive developmental disorder and either high levels of ethylmercury exposure comparable with those experienced in the United States in the 1990s or 1- or 2-dose measles-mumps-rubella vaccinations.<\/jats:p>","DOI":"10.1542\/peds.2005-2993","type":"journal-article","created":{"date-parts":[[2006,7,6]],"date-time":"2006-07-06T12:42:48Z","timestamp":1152189768000},"page":"e139-e150","source":"Crossref","is-referenced-by-count":260,"title":["Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations"],"prefix":"10.1542","volume":"118","author":[{"given":"Eric","family":"Fombonne","sequence":"first","affiliation":[{"name":"Department of Psychiatry, McGill University, Montreal Children's Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Zakarian","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, McGill University, Montreal Children's Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bennett","sequence":"additional","affiliation":[{"name":"Lester B. Pearson School Board, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyan","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, McGill University, Montreal Children's Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"McLean-Heywood","sequence":"additional","affiliation":[{"name":"Lester B. Pearson School Board, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2006,7,1]]},"reference":[{"key":"2021120823055406300_R1","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994"},{"key":"2021120823055406300_R2","doi-asserted-by":"crossref","unstructured":"Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics.\u20082004;(113). Available at: www.pediatrics.org\/cgi\/content\/full\/113\/5\/e472","DOI":"10.1542\/peds.113.5.e472"},{"key":"2021120823055406300_R3","unstructured":"National Research Council. Educating Children With Autism. Washington, DC: National Academy Press; 2001"},{"key":"2021120823055406300_R4","doi-asserted-by":"crossref","unstructured":"Smith T, Groen AD, Wynn JW. Randomized trial of intensive early intervention for children with pervasive developmental disorder. Am J Ment Retard.\u20082000;105:269\u2013285","DOI":"10.1352\/0895-8017(2000)105<0269:RTOIEI>2.0.CO;2"},{"key":"2021120823055406300_R5","doi-asserted-by":"crossref","unstructured":"Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with autism. J Child Psychol Psychiatry.\u20082004;45:212\u2013229","DOI":"10.1111\/j.1469-7610.2004.00215.x"},{"key":"2021120823055406300_R6","doi-asserted-by":"crossref","unstructured":"Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disorder.\u20082003a;33:365\u2013382","DOI":"10.1023\/A:1025054610557"},{"key":"2021120823055406300_R7","doi-asserted-by":"crossref","unstructured":"Fombonne E. Epidemiological studies of autism and pervasive developmental disorders. In: Volkmar F, ed. Handbook of Autism and Pervasive Developmental Disorders. 3rd ed. New York, NY: Wiley & Sons; 2005:42\u201369","DOI":"10.1002\/9780470939345.ch2"},{"key":"2021120823055406300_R8","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA.\u20082001;285:3093\u20133099","DOI":"10.1001\/jama.285.24.3093"},{"key":"2021120823055406300_R9","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry.\u20082005;162:1133\u20131141","DOI":"10.1176\/appi.ajp.162.6.1133"},{"key":"2021120823055406300_R10","doi-asserted-by":"crossref","unstructured":"Fombonne E. The prevalence of autism. JAMA.\u20082003;289:1\u20133","DOI":"10.1001\/jama.289.1.87"},{"key":"2021120823055406300_R11","doi-asserted-by":"crossref","unstructured":"Fombonne E. Is there an epidemic of autism?Pediatrics.\u20082001;107:411\u2013413","DOI":"10.1542\/peds.107.2.411"},{"key":"2021120823055406300_R12","doi-asserted-by":"crossref","unstructured":"Gernsbacher MA, Dawson M, Goldsmith HH. Three reasons not to believe in an autism epidemic. Curr Dir Psychol Sci.\u20082005;14:55\u201358","DOI":"10.1111\/j.0963-7214.2005.00334.x"},{"key":"2021120823055406300_R13","doi-asserted-by":"crossref","unstructured":"Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. The incidence of autism in Olmsted County, Minnesota, 1976\u20131997: results from a population-based study. Arch Pediatr Adolesc Med.\u20082005;159:37\u201344","DOI":"10.1001\/archpedi.159.1.37"},{"key":"2021120823055406300_R14","doi-asserted-by":"crossref","unstructured":"Gurney JG, Fritz MS, Ness KK, Sievers P, Newschaffer CJ, Shapiro EG. Analysis of prevalence trends of autism spectrum disorder in Minnesota. Arch Pediatr Adolesc Med.\u20082003;157:622\u2013627","DOI":"10.1001\/archpedi.157.7.622"},{"key":"2021120823055406300_R15","doi-asserted-by":"crossref","unstructured":"Newschaffer CJ, Falb MD, Gurney JG. National autism prevalence trends from United States special education data. Pediatrics.\u20082005;115(3). Available at: www.pediatrics.org\/cgi\/content\/full\/115\/3\/e277","DOI":"10.1542\/peds.2004-1958"},{"key":"2021120823055406300_R16","doi-asserted-by":"crossref","unstructured":"Arndt TL, Stodgell CJ, Rodier PM. The teratology of autism. Int J Dev Neurosci.\u20082005;23:189\u2013199","DOI":"10.1016\/j.ijdevneu.2004.11.001"},{"key":"2021120823055406300_R17","doi-asserted-by":"crossref","unstructured":"Wakefield A, Murch S, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet.\u20081998;351:637\u2013641","DOI":"10.1016\/S0140-6736(97)11096-0"},{"key":"2021120823055406300_R18","doi-asserted-by":"crossref","unstructured":"Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med.\u20082002;347:1477\u20131482","DOI":"10.1056\/NEJMoa021134"},{"key":"2021120823055406300_R19","doi-asserted-by":"crossref","unstructured":"Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet.\u20082004;364:963\u2013969","DOI":"10.1016\/S0140-6736(04)17020-7"},{"key":"2021120823055406300_R20","doi-asserted-by":"crossref","unstructured":"DeStefano F, Bhasin TK, Thompson WW, Yeargin-Allsopp M, Boyle C. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics.\u20082004;113:259\u2013266","DOI":"10.1542\/peds.113.2.259"},{"key":"2021120823055406300_R21","doi-asserted-by":"crossref","unstructured":"Chen W, Landau S, Sham P, Fombonne E. No evidence for links between autism, MMR and measles virus. Psychol Med.\u20082004;34:543\u2013553","DOI":"10.1017\/S0033291703001259"},{"key":"2021120823055406300_R22","doi-asserted-by":"crossref","unstructured":"Dales L, Hammer S, Smith N. Time trends in autism and MMR immunization coverage in California. JAMA.\u20082001;285:1183\u20131185","DOI":"10.1001\/jama.285.9.1183"},{"key":"2021120823055406300_R23","doi-asserted-by":"crossref","unstructured":"Taylor B, Miller E, Farrington C, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet.\u20081999:353:2026\u20132029","DOI":"10.1016\/S0140-6736(99)01239-8"},{"key":"2021120823055406300_R24","doi-asserted-by":"crossref","unstructured":"Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics. 2001;108(4). Available at: www.pediatrics.org\/cgi\/content\/full\/108\/4\/e58","DOI":"10.1542\/peds.108.4.e58"},{"key":"2021120823055406300_R25","unstructured":"Institute of Medicine. Immunization Safety Review: Vaccines and Autism. Washington, DC: National Academies Press; 2004"},{"key":"2021120823055406300_R26","doi-asserted-by":"crossref","unstructured":"Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev.\u20082005;(4):CD004407","DOI":"10.1002\/14651858.CD004407.pub2"},{"key":"2021120823055406300_R27","doi-asserted-by":"crossref","unstructured":"Jansen VA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science.\u20082003;301:804","DOI":"10.1126\/science.1086726"},{"key":"2021120823055406300_R28","doi-asserted-by":"crossref","unstructured":"Ball L, Ball R, Pratt D. An assessment of thimerosal use in childhood vaccines. Pediatrics.\u20082001;107:1147\u20131154","DOI":"10.1542\/peds.107.5.1147"},{"key":"2021120823055406300_R29","doi-asserted-by":"crossref","unstructured":"Halsey NA, Hyman SL, Conference Writing P. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12\u201313, 2000. Pediatrics.\u20082001;107(5). Available at: www.pediatrics.org\/cgi\/content\/full\/107\/5\/e84","DOI":"10.1542\/peds.107.5.e84"},{"key":"2021120823055406300_R30","doi-asserted-by":"crossref","unstructured":"Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatrics.\u20082004;114:584\u2013591","DOI":"10.1542\/peds.2003-1177-L"},{"key":"2021120823055406300_R31","doi-asserted-by":"crossref","unstructured":"Heron J, Golding J. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association. Pediatrics.\u20082004;114:577\u2013583","DOI":"10.1542\/peds.2003-1176-L"},{"key":"2021120823055406300_R32","doi-asserted-by":"crossref","unstructured":"Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA.\u20082003;290:1763\u20131766","DOI":"10.1001\/jama.290.13.1763"},{"key":"2021120823055406300_R33","doi-asserted-by":"crossref","unstructured":"Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics.\u20082003;112:1039\u20131048","DOI":"10.1542\/peds.112.5.1039"},{"key":"2021120823055406300_R34","doi-asserted-by":"crossref","unstructured":"Madsen KM, Lauritsen MB, Pedersen CB, et al. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics.\u20082003;112:604\u2013606","DOI":"10.1542\/peds.112.3.604"},{"key":"2021120823055406300_R35","doi-asserted-by":"crossref","unstructured":"Stehr-Green P, Tull P, Stellfeld M, Mortenson PB, Simpson D. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med.\u20082003;25:101\u2013106","DOI":"10.1016\/S0749-3797(03)00113-2"},{"key":"2021120823055406300_R36","doi-asserted-by":"crossref","unstructured":"Geier DA, Geier MR. Thimerosal in childhood vaccines, neurodevelopmental disorders, and heart disease in the United States. J Am Phys Surg.\u20082003;8:6\u201311","DOI":"10.1080\/1363849031000139315"},{"key":"2021120823055406300_R37","doi-asserted-by":"crossref","unstructured":"Geier DA, Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr Rehabil.\u20082003;6:97\u2013102","DOI":"10.1080\/1363849031000139315"},{"key":"2021120823055406300_R38","doi-asserted-by":"crossref","unstructured":"Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics.\u20082004;114:793\u2013804","DOI":"10.1542\/peds.2004-0434"},{"key":"2021120823055406300_R39","doi-asserted-by":"crossref","unstructured":"Ip P, Wong V, Ho M, Lee J, Wong W. Mercury exposure in children with autistic spectrum disorder: case-control study. J Child Neurol.\u20082004;19:431\u2013434","DOI":"10.1177\/088307380401900606"},{"key":"2021120823055406300_R40","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet.\u20082002;360:1737\u20131741","DOI":"10.1016\/S0140-6736(02)11682-5"},{"key":"2021120823055406300_R41","unstructured":"Kennedy RF Jr. Deadly immunity. Available at: www.rollingstone.com\/politics\/story. Accessed June 20, 2005"},{"key":"2021120823055406300_R42","unstructured":"Kirby D. Evidence of Harm: Mercury in Vaccines and the Autism Epidemic\u2014A Medical Controversy. New York, NY: St. Martin\u2019s Press; 2005"},{"key":"2021120823055406300_R43","unstructured":"Associated Press. Boy with autism dies after chelation therapy. Available at: www.msnbc.msn.com\/id\/9074208. Accessed May 12, 2006"},{"key":"2021120823055406300_R44","doi-asserted-by":"crossref","unstructured":"Bryson SE, Clark BS, Smith IM. First report of a Canadian epidemiological study of autistic syndromes. J Child Psychol Psychiatry.\u20081998;4:433\u2013445","DOI":"10.1111\/j.1469-7610.1988.tb00735.x"},{"key":"2021120823055406300_R45","unstructured":"Ministe\u0300re de la Sante\u0301 et des Services Sociaux du Que\u0301bec. Protocole d'immunisation du Que\u0301bec. 1st ed. 2nd revision. Ministe\u0300re de la Sante\u0301 et des Services Sociaux du Que\u0301bec; 1992"},{"key":"2021120823055406300_R46","unstructured":"Ministe\u0300re de la Sante\u0301 et des Services Sociaux du Que\u0301bec. Protocole d'immunisation du Que\u0301bec. Que\u0301bec, Canada: Ministe\u0300re de la Sante\u0301 et des Services Sociaux du Que\u0301bec; 1995"},{"key":"2021120823055406300_R47","unstructured":"Ministe\u0300re de la Sante\u0301 et des Services Sociaux du Que\u0301bec. Protocole d'immunisation du Que\u0301bec. 2nd ed, avril 1995, ainsi que ses mises a\u0300 jour de\u0301cembre 1995 et octobre. Que\u0301bec, Canada: Ministe\u0300re de la Sante\u0301 et des Services Sociaux du Que\u0301bec; 1997"},{"key":"2021120823055406300_R48","unstructured":"Ministe\u0300re de la Sante\u0301 et des Services Sociaux du Que\u0301bec. Protocole d'immunisation du Que\u0301bec. 4th ed, avril 1999, ainsi que ses mises a\u0300 jour avril; Que\u0301bec, Canada: Ministe\u0300re de la Sante\u0301 et des Services Sociaux du Que\u0301bec; 2002"},{"key":"2021120823055406300_R49","unstructured":"Ministe\u0300re de la Sante\u0301 et des Services Sociaux du Que\u0301bec. Protocole d'immunisation du Que\u0301bec. 5th ed, avril 2004, ainsi que ses mises a\u0300 jour septembre et novembre 2004. Available at: www.msss.gouv.qc.ca\/sujets\/santepub\/preventioncontrole\/immunisation\/fs_immunisation.html. Accessed January 30, 2006"},{"key":"2021120823055406300_R50","unstructured":"Hudson P, Allard R, Joseph L, Valiquette L. Vaccine coverage of 2-year-old children in Montreal, 2003. Communication at the 6th Canadian Immunization Conference; December 5\u20138, 2004; Montreal, Quebec, Canada"},{"key":"2021120823055406300_R51","unstructured":"Charbonneau S, Riou D, Grignon R. Enque\u0302te vaccinale aupre\u0300s des enfants de 2\u20132 ans du territoire du DSC Cite\u0301 de la Sante\u0301 de Laval. Laval, Que\u0301bec, Canada: De\u0301partement de Sante\u0301 Communautaire; 1987:51"},{"key":"2021120823055406300_R52","unstructured":"Landry M, Valiquette L, Allard R, Cionti M, Chre\u0301tien S. Enque\u0302te sur la couverture vaccinale des enfants de 24\u201330 mois. DSC Cite\u0301 de la Sante\u0301 de Laval et DSC Maisonneuve-Rosemont; Presented at: the 3rd Quebec Colloquium of Infectious Disease; Quebec, Canada; November 1992"},{"key":"2021120823055406300_R53","unstructured":"Lafontaine G, Sauvageau Y. Couverture vaccinale des enfants age\u0301s de 2 ans du territoire du DSC de l'Hopital Charles Lemoyne. Quebec, Canada: De\u0301partement de Sante\u0301 Communautaire de l'Hopital Charles Lemoyne;\u20081990:36"},{"key":"2021120823055406300_R54","unstructured":"Marin-Lira A, Soto JC. Un regard aux e\u0301tudes sur la couverture vaccinale au Que\u0301bec. Document de travail. Que\u0301bec, Canada: Direction de la Sante\u0301 Publique de Laval; 1996:24"},{"key":"2021120823055406300_R55","doi-asserted-by":"crossref","unstructured":"De Wals P, De Serres G et Niyonsenga T. Effectiveness of a Mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA.\u20082001;285:177\u2013181","DOI":"10.1001\/jama.285.2.177"},{"key":"2021120823055406300_R56","unstructured":"SAS Institute. SAS\/STST User's Guide, Version 6. 4th ed. Vol 2. Cary, NC: SAS Institute; 1990"},{"key":"2021120823055406300_R57","unstructured":"Allison P. Logistic regression using the SAS system: theory and application. Cary, NC: SAS Institute Inc and John Wiley; 2001"},{"key":"2021120823055406300_R58","unstructured":"World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992"},{"key":"2021120823055406300_R59","doi-asserted-by":"crossref","unstructured":"Kielinen M, Linna S-L, Moilanen I. Autism in Northern Finland. Eur Child Adolesc Psychiatr.\u20082000;9:162\u2013167","DOI":"10.1007\/s007870070039"},{"key":"2021120823055406300_R60","unstructured":"Direction de l'adaptation scolaire et des services complementaires. Students With Handicaps, Social Maladjustments, or Learning Difficulties: Definitions. Gouvernement duq Ue\u0301bec. Ministere de l'Education, 2000-00-0078. Quebec, Canada: Bibliotheque Nationale duq Ue\u0301bec; 2000"},{"key":"2021120823055406300_R61","doi-asserted-by":"crossref","unstructured":"Croen LA, Grether JK, Hoogstrate J, Selvin S. The changing prevalence of autism in California. J Autism Dev Disord.\u20082002;32:207\u2013215","DOI":"10.1023\/A:1015453830880"},{"key":"2021120823055406300_R62","doi-asserted-by":"crossref","unstructured":"Laidler JR. US Department of Education data on \u201cautism\u201d are not reliable for tracking autism prevalence. Pediatrics.\u20082005;116:120\u2013124","DOI":"10.1542\/peds.2004-2341"},{"key":"2021120823055406300_R63","doi-asserted-by":"crossref","unstructured":"Smeeth L, Rodrigues LC, Hall AJ, Fombonne E, Smith PG. Evaluation of adverse effects of vaccines: the case-control approach. Vaccine.\u20082002;20:2611\u20132617","DOI":"10.1016\/S0264-410X(02)00147-0"},{"key":"2021120823055406300_R64","doi-asserted-by":"crossref","unstructured":"Jick H, Kaye JA. Autism and DPT vaccination in the United Kingdom. N Engl J Med.\u20082004;350:2722\u20132723","DOI":"10.1056\/NEJM200406243502623"},{"key":"2021120823055406300_R65","doi-asserted-by":"crossref","unstructured":"Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics.\u20082001;108:1155\u20131161","DOI":"10.1542\/peds.108.5.1155"},{"key":"2021120823055406300_R66","doi-asserted-by":"crossref","unstructured":"Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatry.\u20082005;46:572\u2013579","DOI":"10.1111\/j.1469-7610.2005.01425.x"},{"key":"2021120823055406300_R67","doi-asserted-by":"crossref","unstructured":"Gillberg C, Heijbel H. MMR and autism. Autism.\u20081998;2:423\u2013424","DOI":"10.1177\/1362361398024007"},{"key":"2021120823055406300_R68","doi-asserted-by":"crossref","unstructured":"Lord C, Shulman C, DiLavore P. Regression and word loss in autistic spectrum disorders. J Child Psychol Psychiatry.\u20082004;45:936\u2013955","DOI":"10.1111\/j.1469-7610.2004.t01-1-00287.x"},{"key":"2021120823055406300_R69","doi-asserted-by":"crossref","unstructured":"Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ.\u20082002;324:393\u2013396","DOI":"10.1136\/bmj.324.7334.393"},{"key":"2021120823055406300_R70","doi-asserted-by":"crossref","unstructured":"Fombonne E, Heavey L, Smeeth L, et al. Validation of the diagnosis of autism in general practitioner records. BMC Public Health.\u20082004;4:5","DOI":"10.1186\/1471-2458-4-5"},{"key":"2021120823055406300_R71","doi-asserted-by":"crossref","unstructured":"Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA.\u20081999;282:47\u201353","DOI":"10.1001\/jama.282.1.47"},{"key":"2021120823055406300_R72","doi-asserted-by":"crossref","unstructured":"McBrien J, Murphy J, Gill D, Cronin M, O'Donovan C, Cafferkey MT. Measles outbreak in Dublin, 2000. Pediatr Infect Dis J.\u20082003;22:580\u2013584","DOI":"10.1097\/01.inf.0000073059.57867.36"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/1\/e139\/1011581\/zpe0070600e139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/1\/e139\/1011581\/zpe0070600e139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T22:09:57Z","timestamp":1639001397000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/118\/1\/e139\/69581\/Pervasive-Developmental-Disorders-in-Montreal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,1]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2006,7,1]]},"published-print":{"date-parts":[[2006,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-2993","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.14711.472227","asserted-by":"object"}]},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,1]]}}}